Who are Mepolizumab 250's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Asthma therapies, anti IL5 receptor antibodies, EXDENSUR, Mepolizumab Injection [Nucala], Fasenra®, Benralizumab Prefilled Syringe.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mepolizumab-250.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Mepolizumab 250 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mepolizumab 250 (Mepolizumab 250) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-IL-5 monoclonal antibody. Area: Immunology.

phase 2 Anti-IL-5 monoclonal antibody IL-5 Immunology Biologic Live · refreshed every 30 min

Target snapshot

Mepolizumab 250 (Mepolizumab 250) — GlaxoSmithKline. Interleukin-5 antagonist

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Mepolizumab 250 TARGET	Mepolizumab 250	GlaxoSmithKline	phase 2	Anti-IL-5 monoclonal antibody	IL-5
Asthma therapies	Asthma therapies	Genentech, Inc.	marketed	Monoclonal antibodies (multiple agents with different targets)	IgE, IL-5, IL-4 receptor alpha (varies by specific agent)
anti IL5 receptor antibodies	anti IL5 receptor antibodies	Scarlata, Simone, M.D.	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5 receptor (IL-5R)
EXDENSUR	DEPEMOKIMAB-ULAA	GLAXOSMITHKLINE LLC	marketed		IL-5
Mepolizumab Injection [Nucala]	Mepolizumab Injection [Nucala]	KU Leuven	marketed	IL-5 antagonist monoclonal antibody	IL-5 (Interleukin-5)
Fasenra®	Fasenra®	AstraZeneca	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5Rα (interleukin-5 receptor alpha)
Benralizumab Prefilled Syringe	Benralizumab Prefilled Syringe	Nantes University Hospital	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5 receptor alpha (IL-5Rα)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-IL-5 monoclonal antibody class)

GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mepolizumab 250 — Competitive Intelligence Brief. https://druglandscape.com/ci/mepolizumab-250. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab